Dandruff and seborrheic dermatitis: Use of medicated shampoos

Hair and Scalp Diseases: Medical, Surgical, and Cosmetic Treatments

Volumn , Issue , 2008, Pages 73-90

  Hickman, Janet G ^a  

^a The Education and Research Foundation Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863716625     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (156)

1. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51(5):785-798.
2. Shiel S, Gray J, Engasser P, eds. Dandruff and the Sensitive Scalp. Cosmetic Considerations. International Congress and Symposium Series No 253. London, UK: The Royal Society of Medicine Press Limited, 2004:1-37.
3. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc 2005; 10(3):194-197.
4. Mastrolonardo M, Diaferio A, Vendemiale G, et al. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self-sufficiency. Acta Derm Venereol 2004; 84(4):285-287.
5. Del Rosso JQ, Management of seborrheic dermatitis of the scalp: focus on ciclopirox 1% shampoo. Cosmet Dermatol 2005; 18(7):473-480.
6. Chen SC, Yeung J, Chren MM. Scalpdex. A quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002; 138(6):803-807.
7. Schwartz JR, Cardin CW, Dawson TL. Dandruff and seborrheic dermatitis. In: Barran R, Maibach HI, eds. Textbook of Cosmetic Dermatology. 3rd ed. New York: Taylor and Francis, 2005:259-272.
8. Hickman JG, Wang X, King B, et al. Dandruff part I: scalp disease prevalence in Caucasians, African-Americans and Chinese and the effects of shampoo frequency on scalp health. Poster presented at the American Academy of Dermatology Meeting, New Orleans, LA, 2002.
9. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson's disease: a survey of (im)possible links. Med Hypotheses 2003; 60(6):907-911.
10. Binder RL, Jonelis F. Seborrheic dermatitis in neuroleptic-induced Parkinsonism. Arch Dermatol 1983; 119(6):473-475.
11. Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrheic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol 1990; 122(1):71-76.
12. Martignoni E, Godi L, Pacchetti C, et al. Is seborrhea a sign of autonomic impairment in Parkinson's disease? J Neural Transm 1997; 104(11-12):1295-1304.
13. Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985; 13(6):947-951.
14. Zanzanaro PCQ, McGirt LY, Mamelak AJ, et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: An institutional urban clinical experience. J Am Acad Dermatol 2006; 54(4):581-588.
15. Groisser D, Bottone EJ, Lebwohl M. Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1989; 20(5):770-773.
16. Wishner AJ, Teplitz ED, Goodman DS. Pityrosporum, ketoconazole, and seborrheic dermatitis. J Am Acad Dermatol 1985; 17(1):140-141.
17. Ford GP, Farr PM, Ive FA, et al. The response of seborrheic dermatitis to ketoconazole. Br J Dermatol 1984; 111(5):603-607.
18. Dahl M. Management of the scaling scalp. Curr Concepts Skin Dis 1983; 4(4):15-19.
19. Verhaegen MJB. The aquatic ape theory: evidence and a possible scenario. Med Hypotheses 1985; 16(1):17-32.
20. Cunnane SC. The aquatic ape theory reconsidered. Med Hypotheses 1980; 6(1):49-58.
21. Hardy A. Was man more aquatic in the past? New Scientist 1960; 7:642.
22. Mayser P, Stapelkamp H, Kramer HJ, et al. Pityrialactone - a new fluorochrome from the tryptophan metabolism of Malassezia furfur. Antonie Van Leeuwenhoek 2003; 84(3):185-191.
23. Mayser P, Shafer U, Kramer HJ, et al. Pityriactrin - an ultraviolet-absorbing indole alkaloid from the yeast Malassezia furfur. Arch Dermatol Res 2002; 294(3):131-134.
24. Malassez L. Note sur le champignon du pityriasis simple. Arch Physiol Norm Pathol (Series 2) 1874; 1:451-464.
25. Saint-Leger D. Histoire des pellicules et pellicules de l'histoire: un homage a Raymond Sabouraud. Ann Dermatol Venereol 1990; 117(1):23-27.
26. Kligman AM, McGinley KJ, Leyden JJ. The nature of dandruff. J Soc Cosmet Chem 1976; 27(3): 111-139.
27. Leyden JJ, McGinley KJ, Kligman AM. Role of microorganisms in dandruff. Arch Dermatol 1976; 112(3):333-338.
28. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 111:235-242.
29. Sudan BJL. Ketoconazole, leukotrienes, Paf-acether and nicotine as a hapten: the possible aetiology of seborrheic dermatitis. Med Hypotheses 1987; 23(1):33-38.
30. Broberg A, Faergemann J. Infantile seborrheic dermatitis and Pityrosporum ovale. Br J Dermatol 1989; 120:359-362.
31. Ruiz-Maldonado R, Lopez-Martinez R, Chavarria ELP, et al. Pityrosporum ovale in infantile seborrheic dermatitis. Ped Dermatol 1989; 6(1):16-20.
32. Hickman JG, Maczulak A, Slife C, et al. Is the Filamentous Form of Pityrosporum Involved in Dandruff? Poster, American Academy of Dermatology Scientific Exhibit. Atlanta, Georgia, Nov 30 thru Dec 5, 1990.
33. Dankner WM, Spector SA, Fierer J, et al. Malassezia fungemia in neonates and adults: complication of hyperalimentation. Rev Infec Dis 1987; 9(4):743-753.
34. Faergemann J, Bernander S. Micro-aerophilic and anaerobic growth of Pityrosporum species. Sabouraudia 1981; 19(2):117-121.
35. Porro MN, Passi S, Caprilli F, et al. Growth requirements and lipid metabolism of Pityrosporum orbiculare. J Invest Dermatol 1976; 66(3):178-182.
36. McGinley KJ, Leyden JJ, Marples RR, et al. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol 1975. 64(6):401-405.
37. Saint-Leger D, Kligman AM, Stoudemayer TJ. The role of the resident microflora in the pathogenesis of dandruff. J Soc Cosmet Chem 1989; 40(2):109-117.
38. Heng MCY, Barker DC, Haberfelde G. Correlation of Pityrosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23(1):82-86.
39. Schmidt A. Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders. Cutis 1997; 59(1):21-24.
40. Bergbrant IM, Faergemann J. Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol 1989; 69(4):332-335.
41. Morishita N, Sei Y, Sugita T. Molecular analysis of Malassezia microflora from patients with pityriasis versicolor. Mycopathologia 2006; 161(2):61-65.
42. Sugita T, Tajima M, Takashima M, et al. A new yeast, Malassezia yamatoensis, isolated from a patient with seborrheic dermatitis, and its distribution in patients and healthy subjects. Microbiol Immunol 2004; 48(8):579-583.
43. Gemmer CM, DeAngelis YM, Theelen B, et al. Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40(9):3350-3357.
44. Larocco M, Dorenbaum A, Robinson A, et al. Recovery of Malassezia pachydermatis from eight infants in a neonatal intensive care nursey: clinical and laboratory features. Pediatr Infect Dis J 1988; 7(6):398-401.
45. Gueho E, Simmons RB, Pruitt WR, et al. Association of Malassezia pachydermatis with systemic infections of humans. J Clin Microbiol 1987; 25(9):1789-1790.
46. Gupta AK, Kohli Y, Summerbell RC, et al. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39, 243-251.
47. Gupta AK, Nicol KA. Seborrheic dermatitis of the scalp: etiology and treatment. J Drugs Dermatol 2004 3(2):155-158.
48. Parry ME, Sharpe GR. Seborrheic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139(2):254-263.
49. Faergemann J. Pityrosporum infections. J Am Acad Dermatol 1994; 31(3):S18-S20.
50. Kieffer M, Bergbrant IM, Faergemann JF, et al. Immune reactions to pityrosporum ovale in adult patients with atopic and seborrheic dermatitis. J Am Acad Dermatol 1990; 22(5):739-742.
51. Ashbee HR, Fruin A, Holland KT, et al. Humoral immunity to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp Dermatol 1994; 3(5):227-233.
52. Belew PW, Rosenberg EW, Jennings BR. Activation of the alternative pathway of complement by Malassezia ovalis (Pityrosporum ovale). Mycopathologia 1980; 70(3):187-191.
53. Rosenberg EW, Belew P, Bale G. Effect of topical applications of heavy suspensions of killed Malassezia ovalis on rabbit skin. Mycopathologia 1980; 72(3):147-154.
54. Skinner RB, Noah PW, Zanolli MD, et al. The pathogenic role of microbes in seborrheic dermatitis. Arch Dermatol 1986; 122(1):16-17.
55. Bergbrant IM, Johansson S, Robbins D, et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16(5):331-338.
56. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum ovale: cultural and immunological and clinical studies. Acta Derm Venereol Suppl 1991; 167:1-36.
57. Faergemann J, Bergbrant IM, Dohse M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144(3):549-556.
58. Oh C, Kim A, Kuo I, et al. Lipids on the Malassezia furfur cell wall inhibit preinflammatory cytokine preduction in human monocytes by downregulating the toll-like receptor 2: immunomodulatory role of Malassezia furfur. Abstract of papers 76066th Annual Meeting of The Society for Investigative Drmatology, 2005, St. Louis, MO.
59. Baroni A, Orlando M, Donnarumma G, et al. Toll-like receptor 2(TLR-2) mediates intracellular signalling in human ketatinocytes in response to Malassezia furfur. Arch Dermatol Res 2006; 297(7):280-288.
60. Watanabe S, Kano R, Sato H, et al. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol 2001; 116(5):769-773.
61. Ishibashi Y, Sugita T, Nishikawa A. Cytokine secretion profile of human keratinocytes exposed to Malassezia yeasts. FEMS Immunol Med Microbiol Oct 27, 2006 [Epub ahead of print].
62. Marples RR, Downing DT, Kligman AM. Influence of Pityrosporum species in the generation of free fatty acids in human surface lipids. J Invest Dermatol 1972; 58(3):155-159.
63. Troller JA. Model system for the investigation of dandruff. J Soc Cosmet Chem 1971; 22(3):187-198.
64. DeAngelis Y, Gemmer C, Kaczvinsky JR, et al. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc 2005; 10(3):295-297.
65. Slife CW, Solbeck, AH, Maczulak AE, et al. Is dandruff a hyperproliferative condition? Poster presentation 1991; American Academy of Dermatology Scientific Exhibit, Dallas, TX, December 7-12, 1991.
66. Marks R, Pearse AD, Walker AP. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112(4):415-422.
67. Warner RR, Schwartz JR, Boissy Y, et al. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol 2001; 45(6):897-903.
68. Simon M, Bernard D, Minondo AM, et al. Persistence of both peripheral and non-peripheral corneodesmosomes in the upper stratum corneum of winter xerosis skin versus only peripheral in normal skin. J Invest Dermatol 2001; 116(1):23-30.
69. Rawlings A, Harding C, Watkinson A, et al. The effect of glycerol and humidity on desmosome degradation in stratum corneum. Arch Dermatol Res 1995; 287(5):457-464.
70. Teresi D. Chemistry: alchemy and beyond. In: Lost Discoveries: the Ancient Roots of Modern Science-From the Babylonians to the Maya. New York: Simon & Schuster, 2002:279-324.
71. Schamberg J. Class VIII.-Anomalies of Secretions of the Glands. In: A Compend of Diseases of the Skin. 4th ed. Philadelphia, PA: P. Blakiston's Son & Co., 1905:268-279.
72. Van Abbe NJ. The investigation of dandruff. J Soc Cosmet Chem 1964; 15(11):609-630.
73. Van Abbe NJ, Dean PM. The clinical evaluation of antidandruff shampoos. J Soc Cosmet Chem 1967; 18:439-453.
74. Kligman AM, Marples RR, Lantis LR, et al. Appraisal of efficacy of antidandruff formulations. J Soc Cosmet Chem 1974; 25(2):73-91.
75. Sheth RA. A comparison of miconazole nitrate and selenium disulfide as anti-dandruff agents. Int J Dermatol 1983; 22(2):123-125.
76. Mayser P, Argenbeaux H, Rippke F. The hair strand test-a new method for testing antifungal effects of antidandruff preparations. J Cosmet Sci 2003; 54(3):263-270.
77. Dandruff, Seborrheic Dermatitis, and Psoriasis Drug Products for Over-the-Counter Human Use; Final Monograph. Federal Register December 4, 1991. Vol. 56, 63554-63569.
78. Roberts DL, Marshall R, Marks R. Detection of the action of salicylic acid on the normal stratum corneum. Br J Dermatol 1980; 103(2):191-196.
79. Kerr KM, Schwartz JR, Kenneally DC, et al. An Investigation of the Impact of PTZ-Containing Anti-Dandruff Shampoos on Scalp Irritation and Itch Associated with Dandruff. Poster presented at IMHRS, Berlin, Germany, 2004.
80. Dandruff, Seborrheic Dermatitis, and Psoriasis Drug Products Containing Coal Tar and Menthol for Over-the-Counter Human Use: Proposed Amendment to the Monograph. Federal Register December 9, 2005. Vol. 70, 73178-73181.
81. McGinley KJ, Leyden JJ. Antifungal activity of dermatological shampoos. Arch Dermatol Res 1982; 272(3-4):339-342.
82. Butterfield W, Roberts MM, Dave VK. Sensitivities of Pityrosporum sp. to selected commercial shampoos. Br J Dermatol 1987; 116(2):233-235.
83. Bulmer AC, Bulmer GS. The antifungal action of dandruff shampoos. Mycopathologia 1999; 147(2):63-65.
84. Nenoff P, Haustein UF, Fiedler A. The antifungal activity of a coal tar gel on Malassezia furfur in vitro. Dermatol. 1995; 191(4):311-314.
85. Lowe NJ, Breding JH, Wortzman MS. New coal tar extract and coal tar shampoos: evaluation by epidermal cell DNA synthesis suppression assay. Arch Dermatol 1982; 118(7):487-489.
86. Hickman JG, Lin GC, Appa Y. Clinical efficacy of two coal-tar containing shampoos in the treatment of moderate to severe seborrheic dermatitis. Poster presentation, American Academy of Dermatology Annual Meeting, March 1999; New Orleans, LA.
87. Merk HF, Mukhtar H, Kaufmann I, et al. Human hair follicle benzo[a]pyrene and benzo[a]pyrene 7,8-diol metabolism: effect of exposure to a coal tar-containing shampoo. J Invest Dermatol 1987; 88(1):71-76.
88. Van Schooten FJ, Moonen EJ, Rhijnsburger E, et al. Dermal uptake of polycyclic aromatic hydrocarbons after hairwash with coal-tar shampoo. Lancet 1994; 344(8935):15050-1506.
89. Mitropoulos P, Norman R. occupational nonsolar risk factors of squamous cell carcinoma of the skin: a population-based case-controlled study. Dermatol Online J 2005; 11(2):5.
90. Imokawa G, Okamoto K. The inhibitory effect of zinc pyrithione on the epidermal proliferation of animal skins. Acta Derm Venereol 1892; 62(6):471-475.
91. Ermolayeva E, Sanders D. Mechanism of pyrithione-induced membrane depolarization in Neospora crassa. Appl Environ Microbiol 1995; 61(9):3385-3390.
92. Weismann K. Chelating drugs and zinc. Dan Med Bull 1986; 33(4):208-211.
93. Dinning AJ, Al-Adham IS, Eastwood, IM, et al. Pyrithione biocides as inhibitors of bacterial ATP synthesis. A Appl Microbiol 1998; 85(1):141-146.
94. Van Cutsem J, Van Gerven F, Fransen J, et al. The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs. J Am Acad Dermatol 1990; 22(6):993-998.
95. Schwartz JR. Product pharmacology and medical actives in achieving therapeutic benefits. Investig Dermatol Symp Proc 2005; 10(3):198-200.
96. Draelos ZD, Kenneally DC, Hodges LT, et al. A comparison of hair quality and cosmetic acceptance following the use of two anti-dandruff shampoos. J Investig Dermatol Symp Proc 2005; 10(3):201-204.
97. Plewig G, Kligman AM. The effect of selenium sulfide on epidermal turnover of normal and dandruff scalps. J Soc Cosmet Chem 1969; 20:767-775.
98. Dandruff, Seborrheic Dermatitis, and Psoriasis Drug Products for Over-the-Counter Human Use; Amendment to the Monograph. Federal Register January 28, 1994. Vol. 59, 4000-4001.
99. Pierard-Franchimont C, Pierard GE, Arrese JE, et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrheic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001; 202(2):171-176.
100. Arrese JE, Pierard-Franchimont C, De Doncker P, et al. Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in Pityriasis capitis. Cutis 1996; 58(3):235-237.
101. Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol 1987; 116(2):213-216.
102. Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993; 28(5): S28-S34.
103. Van Cutsem J, Van Gerven F, Cauwenbergh G, et al. The anti-inflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. J Am Acad Dermatol 1991; 25(2):257-261.
104. Beetens JR, Loots W, Somers Y, et al. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 1986; 35(6):883-891.
105. Alford RH, Vire CG, Cartwright BB, et al. Ketoconazole's inhibition of fungal antigen-induced thymidine uptake by lymphocytes from patients with psoriasis. Am J Med Sci 1986; 29(2):75-80.
106. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother 1983; 24(6):876-882.
107. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrheic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trail. Br J Dermatol 1995; 132(3):441-445.
108. Hickman JG. Nizoral (ketoconazole) shampoo therapy in seborrheic dermatitis. J Int Postgrad Med 1990; 2(1):14-17.
109. Hickman JG, Whitmore CW, Barranco C. Ketoconazole 2% shampoo: a randomized doubleblind controlled application comparison with selenium sulfide 2.5% shampoo and placebo in the treatment of moderate to severe dandruff. American Academy of Dermatology Scientific Exhibit, 48th Annual Meeting, December 2-7, 1989.
110. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29(6):1008-1012.
111. Altmeyer P, Hoffmann K, et al. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43(Suppl 1):9-12.
112. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36(10):788-792.
113. Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43(Suppl 1):17-20.
114. Abeck D, et al. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol 2004; 43(Suppl 1):13-16.
115. Shuster S, Meynadier J, Kerl H, et al. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141(1):47-52.
116. Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol. 1996; 9(6):388-394.
117. Satchell AC, Saurajen MB, Bell C, et al. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol 2002; 47(6):852-855.
118. Brotherton J. Relative effectiveness of different classes of fungicides against Pityrosporum ovale. Br. J Dermatol 1968; 80(11):749-752.
119. Brotherton J. The sulphur metabolism of Pityrosporum ovale and its inhibition by selenium compounds. J Gen Microbiol. 1967; 49(3):393-400.
120. Leyden JJ, McGinley KJ, Mills OH et al. Effects of sulfur and salicylic acid in a shampoo base in the treatment of dandruff: a double-blind study using corneocyte counts and clinical grading. Cutis 1987; 39(6):557-561.
121. Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Dandruff Control Ingredient. Federal Register December 5, 2005. Vol. 70(232):72448-72449.
122. Schmidt A, Ruhl-Horster B. In vitro susceptibility of Malassezia furfur. Arzneimittelforschung 1996; 46(4):442-444.
123. Squire RA, Goode K. A randomized, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrheic dermatitis. J Dermatolog Treat 2002; 13(2):51-60.
124. Rapaport M. A randomized, controlled clinical trial of four anti-dandruff shampoos. J Int Med Res 1981; 9(2):152-156.
125. Amon R, Hickman J, McCoy J, et al. Comparison of the antidandruff efficacy of several zinc pyrithione shampoos versus antidandruff shampoos containing ketoconazole, coal tar and sulfur. Poster presented at the American Academy of Dermatology Scientific Exhibit March 1999; New Orleans, LA.
126. Neumann PB, Coffindaffer TW, Cothran PE, et al. Clinical investigation comparing 1% selenium sulfide and 2% ketoconazole shampoos for dandruff control. Cosmet Dermatol 1996; 9(12):20-26.
127. Pierard-Franchimont C, Goffin V, Decroix J, et al. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002; 15(6):434-441.
128. Bilhimer WL, Bryant PB, Murray KP, et al. Results of clinical trial comparing 1% pyrithione zinc and 2% ketoconazole shampoos. Cosmet Dermatol 1996; 9(5):34-39.
129. Cauwenbergh G, De Doncker P, Schrooten P, et al. Treatment of dandruff with a 2% ketoconazole scalp gel. A double-blind placebo-controlled study. Int J Dermatol 1986; 25(8):541.
130. Aly R, Katz HI, Kempers SE, et al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatl 2003; 42(Suppl 1):19-22.
131. Faergemann J, Bernander S. The activity in vitro of five different antimycotics against Pityrosporum orbiculare. Acta Derm Venereol 1979; 59(6):521-524.
132. Faergemann J. Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a doubleblind study. Cutis 1988; 42(1):69-71.
133. Faergemann J. Short-term treatment of dandruff with a combination of propylene glycol solution and shampoo. Cutis 1988; 42(2):146.
134. Faergemann J. Management of seborrheic dermatitis and Pityriasis versicolor. Am J Clin Dermatol 2000; 1(2):75-80.
135. Faergemann J, Fredriksson T. Antimycotic activity of propane-1,2-diol (propylene glycol). Sabouraudia 1980; 18:163-166.
136. Package insert, Xolegel. Barrier Therapeutics. September 2006.
137. Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with topical ketoconazole. Lancet 1984; 2(8414):1271-1272.
138. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: A phase III trial. J Drugs Dermatol 2006; 5(7):646-650.
139. Skinner RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 12(5):852-856.
140. Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Int J Dermatol 1977; 16(5):413-417.
141. Bonnetblanc JM, Bernard P. Benzoyl peroxide in seborrheic dermatitis. Arch Dermatol 1986; 122(7):752.
142. Prestia AE. Topical benzoyl peroxide for the treatment of tinea versicolor. A Am Acad Dermatol 1983; 9(2):177-178.
143. Rushton H, Gummer CL, Flasch H. 2-in-1 shampoo technology: state-of-the-art shampoo and conditioner in one. Skin Pharmacol 1994; 7(1-2):78-83.
144. Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol 2003; 149(2):354-362.
145. Pierard-Franchimont C, De Doncker P, Cauwenbergh G, et al. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology 1998; 196(4):474-477.
146. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002; 29(8):489-498.
147. Cornell RC. Atrophogenic potential of alclometasone dipropionate ointment 0.05% vs hydrocortisone ointment 1%. Curr Ther Res 1986; 39(2):260-268.
148. Milani M, Molfetta ADS, Gramazio R, et al. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrheic dermatitis of the scalp: an open-label, multicenter, prospective trial on 180 patients. Curr Med Res Opin 2003; 19(4):342-345.
149. Harding CR, Moore AE, Rogers JS, et al. Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res 2002; 294(5):221-230.
150. Gupta AK, Nicol KA. Seborrheic dermatitis of the scalp: etiology and treatment. J Drugs Dermatol 2004; 3(2):155-158.
151. Meshkinpour A, sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49(1):145-147.
152. Rigopoulos D, Ioannides D, Kalogeromitros D, et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151(5):1071-1075.
153. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006 142(8):1066-1067.
154. High WA, Pandya AG. Pilot trial of 1% Pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol 2006 54(6):1083-1088.
155. Sugita T, Tajima M, Ito T, et al. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005; 43(6):2824-2829.
156. Sugita T, Tajima M, Tsubuku H, et al. A new calcineurin inhibitor, Pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother 2006; 50(8):2897-2898.